Home / Health / CF fighter's life transformed by new medicine
CF fighter's life transformed by new medicine
24 Oct
Summary
- Michelle Shore's lung function improved significantly with Kaftrio.
- She was previously denied a lung transplant due to infection.
- Funding for Kaftrio was secured from NHS England in December 2025.
Michelle Shore, a solicitor from South Yorkshire, has experienced a life-altering recovery thanks to Kaftrio, a new modulator medicine for cystic fibrosis (CF).
Diagnosed with CF at eight months old, Michelle's health was manageable in childhood but declined significantly from her 20s, leading to a lung function of 34% and dependency on oxygen.
In her 30s, rare genetic mutations meant she couldn't benefit from existing CF treatments. After being denied a lung transplant in March 2024 due to an infection, she found hope through an individual trial of Kaftrio, following positive cell response testing in Paris.
Supported by her consultant, she applied for and received funding from NHS England for Kaftrio in December 2025. This treatment has since dramatically improved her health, allowing her to return to work and enjoy life without constant breathlessness.
Michelle is now advocating for increased awareness to ensure no one with CF is "left behind," highlighting the importance of community support and access to innovative therapies.
